Clinical trial NCT03775525: Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
Official title: A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Cancer
Gastric Cancer
Breast Cancer
Pancreatic Cancer
Prostate Cancer Metastatic
Colo-rectal Cancer
Solid Tumor
Solid Carcinoma
Solid Carcinoma of Stomach
Cancer of Stomach
Lymphoma
Sarcoma
Cutaneous T Cell Lymphoma
Head and Neck Squamous Cell Carcinoma
Basal Cell Carcinoma
Cutaneous T-cell Lymphoma
Cutaneous Squamous Cell Carcinoma
Lead sponsor: Genzada Pharmaceuticals USA, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Translational Drug Development
First posted: 2018-12-14
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

Detailed description: This study will evaluate the safety, pharmacokinetics, and pharmacodynamic effects of a novel anti-cancer drug, GZ17-6.02 administered to patients with advanced solid tumors or lymphoma, which have progressed after receiving standard/approved therapy or where there is no approved therapy.

This study will determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of GZ17-6.02 monotherapy and in combination with standard-of-care oncology treatments and to establish the dose of GZ17-6.02 recommended for future monotherapy and combination therapies phase II oncology clinical studies.

Eligibility criteria: General Inclusion Criteria:

* Patients with a pathologically confirmed diagnosis of advanced solid tumors or lymphoma.
* Tumor progression after receiving standard/approved therapies which may include chemotherapy, targeted agents, radio-immuno conjugates, check point inhibitors, where there is no approved therapy; or the patient is intolerant of standard of care or the patient declines standard of care treatment
* One or more metastatic tumors measurable, or evaluable, per RECIST v1.1 Criteria for solid tumors and Lugano Criteria for lymphoma
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
* Life expectancy of at least 3 months
* Age 18 years
* Signed, written IRB-approved informed consent
* A negative pregnancy test (if female)
* Acceptable liver function:

  * Bilirubin ≤ 1.5 times upper limit of normal
  * AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal (if liver metastases are present, then ≤ 5 x ULN is allowed)
* Acceptable renal function:

  o Serum creatinine ≤ 1.5 times institutional ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
* Acceptable hematologic status:

  * Granulocyte ≥ 1500 cells/mm3
  * Platelet count ≥ 100,000 (plt/mm3)
  * Hemoglobin ≥ 9 g/dL
* Urinalysis:

  o No clinically significant abnormalities
* Acceptable coagulation status (for patients on warfarin or other anti-coagulants, a PT/PTT considered by the PI as therapeutically appropriate will be allowed):

  * PT within ≤ 1.5 times normal limits
  * PTT within ≤ 1.5 times normal limits
* For men and women of child-producing potential, the use of effective contraceptive methods during the study
* Fasting glucose ≤ 180 mg/dL
* Albumin ≥ 3.0 g/dL within seven days of initiating protocol treatment

For patients in the GZ17-6.02 plus capecitabine Phase 1b Expansion Cohort 2 (metastatic breast cancer):

* Pathologically confirmed diagnosis of HER2-negative and Hormone Receptor (HR) (estrogen receptor \[ER\] and/or progesterone receptor)-positive metastatic breast cancer;
* Had ≤ 1 prior treatment (not including neoadjuvant or adjuvant treatment);
* Are naïve to capecitabine but not necessarily to fluorouracil (5 FU);
* Eligible for standard-of-care treatment with capecitabine monotherapy.
* Patients in Expansion Cohort 2 with bone-only metastatic disease must have one or more lytic or a mixed lytic-blastic lesions that can be assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI).

For patients in GZ17-6.02 plus capecitabine Phase 1b Expansion Cohort 3 (metastatic colorectal cancer):

* Pathologically confirmed diagnosis of metastatic colorectal cancer;
* Had ≤ 2 prior treatments (not including neoadjuvant or adjuvant treatment);
* Are naïve to capecitabine but not necessarily to 5 FU;
* Eligible for standard-of-care treatment with capecitabine monotherapy.

General Exclusion Criteria: (All patients, unless otherwise specified):

* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.
* Currently taking MAOIs
* Baseline QTc exceeding 450 msec in males, 470 msec in females (using the Fridericia's formula) and/or patients receiving class 1A or class III antiarrhythmic agents;
* Known active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy;
* Pregnant or nursing women.
* NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Treatment with radiation therapy or surgery within 1 month prior to study entry.
* Treatment with chemotherapy, targeted therapeutics (e.g. tyrosine kinase inhibitors, therapeutic antibodies, etc), or investigational therapies within 1 month, or 5 half-lives (whichever is shorter), prior to study entry (6 weeks for nitrosoureas or mitomycin C). For radiopharmaceuticals, within 1 month unless hematopoietic recovery has not returned to pretreatment baseline;
* Unwillingness or inability to comply with procedures required in this protocol;
* Known active infection with HIV, HTLV-1, hepatitis B, hepatitis C or other chronic viral infections that could interfere with the interpretation of study data;
* Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.
* Patients who are currently receiving any other investigational agent;
* Primary Central Nervous System (CNS) malignancies;
* Active CNS metastases requiring treatment or radiotherapy, or which have not been confirmed stable on radiographic imaging for ≥30 days prior to C1D1;
* Patients requiring steroids for neurological signs and symptom stabilization.
* Patients who are unable to successfully discontinue all prohibited medications listed in Appendix 6;
* Patients must not have received a transfusion (platelets or red blood cells) ≤ 2 weeks prior to initiating protocol therapy.

For patients in the GZ17-6.02 monotherapy Dose Escalation Cohort and patients in Expansion Cohort 1:

• Patients with cow's milk allergy or with galactosemia

Phase 1b Expansion Cohort 2 (metastatic breast cancer) and Expansion Cohort 3 (metastatic colorectal cancer):

* Any history of coronary artery disease is exclusionary; New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on the ECG.
* Any conditions or medications that are contraindicated with capecitabine dosing;
* Dihydropyrimidine dehydrogenase (DPD) deficiency;
* Known sensitivity to capecitabine or any of its components or to 5-FU ;
* Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor

  o This includes prior gastrointestinal surgery that would interfere with the oral drug absorption.
* Malignancy other than metastatic breast cancer (Expansion Cohort 2) or metastatic colorectal cancer (Expansion Cohort 3) that required therapy within the preceding 5 years, other than adequately treated:

  * non-melanoma skin cancer or in situ cancer;
  * another cancer that has a very low risk of interfering with the safety or efficacy endpoints of the study, must be approved by the Sponsor medical team.

Primary outcomes:
measure: maximum tolerated dose (MTD)
timeFrame: 18 months
measure: Recommended dose of GZ17-6.02 for future phase II clinical studies
timeFrame: 18 months
measure: Dose-limiting toxicity
timeFrame: 18 months
Secondary outcomes:
measure: Antitumor effect
timeFrame: 18 months
measure: Area Under Concentration Curve
timeFrame: 18 months
measure: Maximum Plasma Concentration (Cmax)
timeFrame: 18 months
measure: Time to Maximum Plasma Concentration (Tmax)
timeFrame: 18 months
measure: Terminal Phase Half-Life (t1/2)
timeFrame: 18 months
measure: Total Body Clearance (CL/F)
timeFrame: 18 months
measure: Apparent Volume of Distribution (Vd/F)
timeFrame: 18 months
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: HonorHealth Research Institute
state: Arizona
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Dallas
country: United States
facility: Baylor Charles A. Sammons Cancer Center
state: Texas
Study officials:
affiliation: Translational Drug Development
name: Kathryn Gazarik
role: STUDY_DIRECTOR
References:
citation: Booth L, West C, Von Hoff D, Dent P. Mechanisms of GZ17-6.02 resistance. Anticancer Drugs. 2022 Jun 1;33(5):415-423. doi: 10.1097/CAD.0000000000001203.